

September 29, 2026

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001
Scrip code: 544889

To,
National Stock Exchange of India Ltd.,
Exchange Plaza,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400051
Symbol: SYMBIOTEC

Sub.: Symbiotec Pharmalab Receives Establishment Inspection Report (EIR) from U.S. FDA for its Pithampur (SEZ) Madhya Pradesh, India facility with VAI classification

Dear Sir/Ma'am,

Symbiotec Pharmalab Limited (“**Symbiotec**”), a research and development-driven, science-based pharmaceutical and biotechnology company, today announced that it has received the Establishment Inspection Report (“**EIR**”) from the U.S. Food and Drug Administration (U.S. FDA) for its manufacturing facility in Pithampur (“**SEZ**”), Madhya Pradesh India with a Voluntary Action Indicated (“**VAI**”) status.

The inspection was conducted at the Company’s manufacturing facility at Pithampur, from August 10, 2026 to August 14, 2026.

This is for your Information and Records.

Thanking you,

For Symbiotec Pharmalab Limited

Salil Jain
Company Secretary & Compliance Officer

Registered Office & Works:

Symbiotec Pharmalab Limited

(Formerly known as Symbiotec Pharmalab Pvt. Ltd.)

385/2, Pigdamber, Rau, Mhow, Indore - 453331, Madhya Pradesh, India

Tel. No.: +91-731-6676405-406 Fax: +91-731-4201222,

Email ID : symbiotec@symbiotec.com, **Website :** www.symbiotec.com

CIN: U24232MP2002PLC015293